Study on Tat Mediated Magnetic Nanoparticles Having Composite Targeting Function

This paper describes a new formulation of magnetic nanoparticles coated by a novel polymer matrix-O-Carboxylmethylated Chitosan (O-CMC) as a drug/gene carrier. The O-CMC magnetic nanoparticles were derivatized with a peptide sequence from the HIV-tat protein and transferrin to improve the translocational property and cellar uptake of the nanoparticles. To evaluate the O-MNPs-Tat-Tf as a drug carrier, Methotrexate (MTX) was incorporated as a model drug and MTX-loaded O-MNPs-Tat-Tf with an average diameter of 75 nm were prepared and characterized by TEM, AFM and VSM.The cytotoxicity of MTX-loaded O-MNPs-Tat-Tf was investigated with C6 cells. The results showed that the MTX-loaded O-MNPs-Tat-Tf retained significant antitumor toxicity.

微球栓塞联合动脉灌注化疗治疗贲门癌肝转移的疗效观察及其对患者远期预后的影响

[目的]观察贲门癌肝转移治疗中微球栓塞联合动脉灌注化疗的疗效及对患者远期预后的影响。[方法]回顾性分析100例贲门癌肝转移患者的基线资料,根据治疗方式的不同将其分为A组(53例,微球栓塞+动脉灌注化疗)和B组(47例,动脉灌注化疗)。比较2组基线资料;比较2组治疗前后吞咽功能、临床疗效、不良反应发生情况;采用Kaplan-Meier法分析2组术后3年生存情况,并行Log-rank检验。[结果]2组性别、年龄、BMI、肿瘤直径、组织分化程度、浸润深度、淋巴结转移、肝转移类型及肝转移直径等基线资料比较,均差异无统计学意义(P>0.05);2组治疗后吞咽功能Ⅲ~Ⅴ级构成比均降低(P<0.05),A组低于B组(P<0.05);A组临床总有效率高于B组(P<0.05);A组疼痛、恶心发生率高于B组(P<0.05);A组1、2、3年生存率均高于B组(P<0.05)。生存曲线显示A组中位生存期长于B组(P<0.05)。[结论]贲门癌肝转移治疗中微球栓塞联合动脉灌注化疗可改善患者的吞咽困难,疗效确切,提高了远期生存率,但会增加不良反应的发生。